All News

Cash-rich pharma is dropping any pretence they are buying cash-strapped biotech for access to innovative technology. What it wants is products. Let’s hope it doesn’t suffocate the feedstock of innovation in the process.

Global research spending soared in 2007, with Microsoft pulling into the lead. But don’t expect a repeat this year, warns Commissioner Potočnik.

The credit crunch is strangling biotech. And with no access to capital, the only way out is to sell to big pharma.

As stock markets turn their backs on the high-risk sectors, France Biotech’s annual survey reveals the depths to which investment has fallen.

Europe’s biotechnology industry needs to speak with one voice and have a single, flagship gathering like the US’s annual BIO conference, says Eric Poincelet.

Who can deliver on science and innovation? I can, says the UK’s new Science Minister, Paul Drayson.